NEW YORK–(BUSINESS WIRE)–Manhattan Scientifics Inc. (OTCQB: MHTX) has invested $30 million and a 10-year effort to commercialize the super-early, non-invasive, non-radioactive cancer diagnostics from Imagion Biosystems (IBX: AX), now in “partnership” with MD Anderson Cancer Center, Houston. The company is awaiting regulatory approval to start human cancer trials.
View the stock chart.
“The very early detection of cancer can ultimately lead to the end of the dreaded disease,” said a cancer doctor.
Manhattan Scientifics founder Marvin Maslow and CEO Manny Tsoupanarias pioneered the development of HDTV, hydrogen fuel cells, haptics, and other advanced space-age technologies.
Maslow said: “We’ve done it before and we’ll do it again and it won’t be hard.” Manny T. continued, “As early stage investors in disruptive technologies, we have seen our market capitalization increase to approach $1.0 billion and fall to $17 million, we intend to create value increased for shareholders in the future.”
About Manhattan Scientifics, Inc.
Manhattan Scientifics Inc. (www.mhtx.com) is focused on technology transfer and commercialization of transformative technologies.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such forward-looking statements. Manhattan Scientifics management believes that buying its stock should be viewed as being on the higher end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.